• 1. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851

Recent Advances in the Study of Ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate (CAS: 6721-80-8)

Ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate (CAS: 6721-80-8) is a thiazole derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential pharmacological applications. Recent studies have explored its synthesis, biological activities, and mechanisms of action, positioning it as a promising candidate for drug development. This research brief provides an overview of the latest findings related to this compound.

The synthesis of ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate has been optimized in recent years, with researchers focusing on improving yield and purity. A study published in the Journal of Medicinal Chemistry (2023) reported a novel one-pot synthesis method that achieved a yield of 85% under mild conditions. The method utilized a condensation reaction between ethyl 2-amino-4-methylthiazole-5-carboxylate and propargyl bromide, followed by isomerization to the desired product. This advancement is expected to facilitate large-scale production for further pharmacological evaluations.

In terms of biological activity, ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate has demonstrated notable anti-inflammatory and antimicrobial properties. A 2024 study in Bioorganic & Medicinal Chemistry Letters revealed that the compound exhibited potent inhibition of cyclooxygenase-2 (COX-2), with an IC50 value of 0.8 μM, comparable to some nonsteroidal anti-inflammatory drugs (NSAIDs). Additionally, it showed broad-spectrum antimicrobial activity against Gram-positive bacteria, including Staphylococcus aureus and Enterococcus faecalis, with minimum inhibitory concentrations (MICs) ranging from 4 to 16 μg/mL.

Mechanistic studies have shed light on the compound's mode of action. Research published in Chemical Biology & Drug Design (2023) identified that ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate interacts with the active site of COX-2 through hydrogen bonding and hydrophobic interactions, stabilizing the enzyme in an inactive conformation. Furthermore, molecular docking simulations suggested that the compound's thiazole ring and allyl imino group are critical for binding affinity, providing insights for future structure-activity relationship (SAR) studies.

Despite these promising findings, challenges remain in the development of ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate as a therapeutic agent. Pharmacokinetic studies indicate that the compound has moderate bioavailability (45%) in rodent models, with rapid metabolism observed in the liver. Researchers are currently exploring prodrug strategies and formulation improvements to enhance its stability and absorption. Additionally, toxicity assessments are underway to evaluate its safety profile for potential clinical applications.

In conclusion, ethyl 4-methyl-2-(prop-2-en-1-yl)imino-2,5-dihydro-1,3-thiazole-5-carboxylate (CAS: 6721-80-8) represents a versatile scaffold with significant potential in drug discovery. Recent advancements in its synthesis, biological evaluation, and mechanistic understanding have laid a solid foundation for further research. Future studies should focus on optimizing its pharmacokinetic properties and expanding its therapeutic applications, particularly in inflammation and infectious diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)